CXCR4 and glioblastoma: Also, preclinical studies showed that inhibition of the CXCR4 might be potentially efficient against other cancers including GBM (170, 171), and the first human clinical trial of plerixafor as an adjunct to combined chemoradiotherapy was conducted in newly diagnosed GBM patients (172) achieving median overall survival of ~21 months.